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Antimycobacterial drug discovery 
using Mycobacteria-infected 
amoebae identifies anti-infectives 
and new molecular targets
Valentin Trofimov1,6, Sébastien Kicka1, Sabrina Mucaria2, Nabil Hanna1,  
Fernando Ramon-Olayo3, Laura Vela-Gonzalez Del Peral3, Joël Lelièvre3, Lluís Ballell3, 
Leonardo Scapozza2, Gurdyal S. Besra  4, Jonathan A. G. Cox5 & Thierry Soldati1
Tuberculosis remains a serious threat to human health world-wide, and improved efficiency of medical 
treatment requires a better understanding of the pathogenesis and the discovery of new drugs. In the 
present study, we performed a whole-cell based screen in order to complete the characterization of 
168 compounds from the GlaxoSmithKline TB-set. We have established and utilized novel previously 
unexplored host-model systems to characterize the GSK compounds, i.e. the amoeboid organisms 
D. discoideum and A. castellanii, as well as a microglial phagocytic cell line, BV2. We infected these 
host cells with Mycobacterium marinum to monitor and characterize the anti-infective activity of the 
compounds with quantitative fluorescence measurements and high-content microscopy. In summary, 
88.1% of the compounds were confirmed as antibiotics against M. marinum, 11.3% and 4.8% displayed 
strong anti-infective activity in, respectively, the mammalian and protozoan infection models. 
Additionally, in the two systems, 13–14% of the compounds displayed pro-infective activity. Our studies 
underline the relevance of using evolutionarily distant pathogen and host models in order to reveal 
conserved mechanisms of virulence and defence, respectively, which are potential “universal” targets 
for intervention. Subsequent mechanism of action studies based on generation of over-expresser 
M. bovis BCG strains, generation of spontaneous resistant mutants and whole genome sequencing 
revealed four new molecular targets, including FbpA, MurC, MmpL3 and GlpK.
Tuberculosis (TB) remains one of the most serious health-threats worldwide with 8 million cases of new infec-
tion annually. In the last few decades, various steps were taken to reduce the burden of TB. However, despite 
the decline in prevalence and mortality, the death count still remains astonishingly high. In 2014, TB killed 1.5 
million people, which makes it one of the most deadly bacterial infectious diseases worldwide1. Furthermore, the 
emergence of multidrug-resistant Mycobacterium tuberculosis (Mtb) has gradually rendered current frontline 
TB therapy inefficient. To reduce the TB burden, it is absolutely necessary to discover new anti-TB drugs and to 
improve methodologies of TB detection and treatment. There are several drug candidates at different stages of the 
development pipeline, including TB-354 in Phase I clinical trial (WHO 2015).
The discovery of new drugs faces many challenges. For example, the low metabolic rate of Mtb significantly 
decreases bactericidal activity of antibiotics2. Drug efficacy is also reduced by the highly impermeable hydro-
phobic mycobacteria cell wall, intracellular degradation and the activity of efflux pumps of the host as well as the 
bacterium3. Additionally, Mtb is able to manipulate the environment inside the alveolar macrophages via mod-
ulation of membrane trafficking4,5, of autophagy6,7, by alteration of the signalling pathways8 and by induction of 
programmed cell death9,10. Finally, Mtb causes the formation of granulomas that both help contain and facilitate 
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dissemination of the infection11,12. Many drugs with a clinically relevant high bactericidal potency show compar-
atively insignificant effects in in vivo infection model systems13.
The high attrition rate may also indicate involvement of additional parameters, such as the influence of 
host-drug and host-pathogen interactions14. The host partially shields the bacteria from anti-TB treatment, 
decreasing the efficiency of various antibiotics15,16. Lastly, one cannot ignore the changes of mycobacterial metab-
olism during infection17, specifically initiation of a dormant, persistent stage18 and Mtb switching from glycolysis 
to fatty acids metabolism19–21.
The influence of the host might also be beneficial to help eradicate the infection by host and pathogen-mediated 
activation of prodrugs and other anti-infective processes, such as ‘nutritional immunity’22. Compounds with such 
activity belong to the ‘defence boosters’ category and act via the activation of the protective mechanisms of the 
host cell. This approach may provide a means by which to discover compounds that act on a broad range of infec-
tious diseases.
Overall, this low success of in vitro and target-based screening strategies recently led to a resurgence of 
whole-cell phenotypic screening23. Unlike target-based approaches, this strategy takes into account many of the 
aforementioned in vivo parameters from the beginning of the screening process. The drawbacks, however, include 
the lack of predefined mechanisms of action of the drug-candidates.
Whole-cell phenotypic screening can be performed either directly with Mtb and human CD14 positive 
peripheral blood mononuclear cells or by using pathogen and host substitutes. Selecting a model is a fine balance 
between experimental costs, ethical, genetic and experimental tractability. M. marinum has recently been adopted 
in many studies24. Mammalian hosts offer high phenotypic relevance to human TB, and are therefore better suited 
to later stages of drug discovery and development. On the other hand, simpler organisms provide less ethical con-
strains and statistical variations, ease of manipulation and high throughput application in early drug discovery 
as well as in focused mechanism of action studies and target verification. In recent years, a variety of host model 
systems have been used for the study of TB, including primates25, rodents26,27, zebrafish28, Drosophila29 and pro-
tozoans30. Two major amoeba systems, Acanthamoeba castellanii and Dictyostelium discoideum, have been used 
to study the course of infection with various pathogenic bacteria31, including screens with M. marinum and other 
virulent mycobacteria32. They are also well-established models of microbial infections and host-pathogen inter-
actions31,33–36, and drug discovery37–39. In addition, the compact and haploid genome of D. discoideum provides 
expanded opportunities for fast and effective genetic engineering.
In the TB drug discovery pipeline, phenotypic screening is followed by molecular target identification through 
mechanism of action studies. There are two main non-exclusive strategies to discovering the molecular targets of 
compounds: direct biochemical methods and genetic interactions methods. The direct approach often involves 
immobilization of the interacting protein, a “fishing” procedure, and crosslinking of the protein to the target 
molecule and purification of the covalent complex. Genetic interactions methods involve analysis of changes of 
genetic expression patterns in the presence or absence of compound. In bacteria, molecular targets are routinely 
identified by generation of spontaneously resistant mutants, verified by whole-genome sequencing or by the use 
of over-expresser mutants. Generally, the integration of multiple complementary methodologies is required to 
fully solve the problem of target identification.
In the present study, we decided to address the lack of data related to the in vivo characterization of com-
pounds from the GSK TB-set, and performed a whole cell-based phenotypic screen, as well as more traditional 
growth and cytotoxicity assays. The screening was followed by molecular target identification studies.
Results
Firstly, compounds were characterized in fluorescence-based phenotypic assays with the use of M. marinum and 
protozoan/mammalian cell systems. The compounds from the GSK TB library were scrutinized for cytotoxic, 
antibiotic and anti-infective properties.
Over 70% of the compounds from the GSK TB-set show antibiotic activities against M. mari-
num. We established an assay to measure the antibiotic and bacteriostatic activity of compounds against M. 
marinum in the absence of the host (Figs 1A–C, S1). Compounds at 10 μM in DMSO, a concentration sim-
ilar to the one used in the original BCG-based screening40, were transferred to 96-well plates containing 105 
GFP-expressing M. marinum per well. Growth was monitored for 35–72 hours, and the total fluorescence inten-
sity was used as a proxy to quantify the bacterial mass. Compared to DMSO alone, we observed reproducible 
10–100% decrease of the fluorescence intensity for 122 compounds out of 168, with 66 showing more than 50% 
inhibition, while 56 displayed 10–50% inhibition. Interestingly, in this antibiotic assay, 46 out of 168 compounds 
were found to have negligible effect (less than 10% inhibition) on bacterial growth (Tables 1 and S1, Fig. 1D). 
We also verified the compounds’ antibiotic activity using the luxCDABE-expressing auto-bioluminescent M. 
marinum strain. Compared to the vehicle control, we observed 81–100% decrease of the fluorescence intensity 
for 111 compounds out of 168, while 37 displayed 11–80% inhibition. Among 168 compounds, 20 were found 
to have negligible effect (less than 10% inhibition) on bacterial growth (Tables 1 and S1, and see Discussion for 
a more detailed comparison of the two sets of results). These two assays allowed us to characterize antibacterial 
activities independent from host-pathogen interactions. Data derived from this assay served as a reference point, 
since broth-based phenotypic screening is one of the core techniques in drug discovery and was used for initial 
establishment of the GSK TB-set40. The fact that the majority of the compounds decreased the rate of M. marinum 
growth indicates high potential for using this mycobacterial strain as a substitute for Mtb in classical antibiotic 
assays. Lack of significant bactericidal activity for certain compounds might be explained by genetic and meta-
bolic differences between M. marinum and Mtb.
www.nature.com/scientificreports/
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Confirmation of the low cytotoxicity of compounds from the GSK TB-set on murine microglial cells. 
In order to estimate the inhibitory activity of each compound on host cell growth, we decided to use both amoeba 
(Fig. 2A) and mammalian cell-based assays. For the latter, high-content phase contrast microscopy of murine 
microglial BV2 cells was used (Figs 2B,C, S2). In brief, 10 μM of each compound in DMSO was transferred to 
96-well plates with each well containing 105 BV2 cells, and incubated for 60 to 72 hours at 37 °C. Distinguishing 
between growth inhibition and cytotoxicity was performed by visual inspection as an end-point measurement 
after 60 hours of incubation in the presence of the compound. Results indicated that at 10 μM, 158 compounds 
did not show significant inhibition of growth (<50% inhibition) on murine microglial cells, we also detected 5 
clearly cytotoxic hits, and 5 fell into the category of mildly cytotoxic compounds.
Confirmation of the low cytotoxicity of compounds from the GSK TB-set on the protozoan 
organism D. discoideum. Basic cellular functions regulated by housekeeping genes are conserved between 
D. discoideum and mammalian cells. Therefore, to assess its suitability to predict the cytotoxicity of compounds, 
we established a D. discoideum-based assay to measure toxic and growth inhibitory activities of compounds 
(Figs 2A, S3A,B). D. discoideum cells expressing GFP-ABD were used for the assay, the total fluorescence signal 
was used for cell quantification, as it is proportional to cell count. The linear relationship between cell biomass 
and the fluorescence/luminescence signals was confirmed by the determination of coefficients of correlation 
between CFU counting, fluorescence measurements (RFU), bioluminescence (RLU) and, and optical density 
(OD) in M. marinum cultures (Fig. S4). Distinguishing between cytotoxic and growth inhibitory properties of 
compounds was performed by visual inspection. Cells were searched for phenotypic characteristics of cell death 
Figure 1. Characterization of antibiotic activities of GSK TB-set compounds. (a) Fluorescent confocal 
microscopy of 105 M. marinum msp12::GFP, 72 hours incubation time in 7H9 broth. The scale bar corresponds 
to 20 µm. (b) Correlation between fluorescence intensity and serial dilution. Serial dilutions of M. marinum 
msp12::GFP, were transferred to 96-well plate. Dilution factor is 3. A relative density unit corresponds to 105 
bacteria. (c) Growth kinetics of M. marinum msp12::GFP in 7H9 broth and in the presence compounds from 
GSK TB-set (color-coded green) of vehicle control (blue), supplemented with 10 μM amikacin (purple), 10 μM 
rifabutin (red) representative experiment from a series with similar outcome. 105 M. marinum expressing 
GFP were transferred to the wells. Fluorescence intensities were measured for 72 hours every 3 hours. (d) Pie 
chart representing summarized results of growth inhibitory activity of 168 compounds in M. marinum growth 
assay. The analyzed set included compounds that displayed inhibition of more than 90% RFU (red), inhibition 
between 30 and 90% (orange), compounds that showed less than 30% inhibition (grey).
www.nature.com/scientificreports/
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such as membrane permeability and loss of substrate attachment. Among the analysed compounds at a 10 µM 
concentration, 144 compounds out of 168 (85.7%) did not display cytotoxic properties (threshold of inhibition 
<50%), we also detected 4 (2.3%) clearly cytotoxic hits (inhibition >80%), and 20 fell into the category of mildly 
cytotoxic compounds (Fig. 2B). Presence of cytotoxic activity for 2.3% of compounds might be explained by 
genetic and metabolic differences between D. discoideum and the mammalian HepG2 cell line used in the original 
cytotoxicity test40. We found 3 hits with cytotoxic activities both in BV2 and D. discoideum growth assays.
Less than 5% of the compounds from the GSK TB-set exert strong anti-infective activity against 
M. marinum inside the A. castellanii protozoan host. We characterized the in vivo activity of the 168 
compounds from the GSK TB-set during infection of A. castellanii with M. marinum (Figs 3A,B, S5). The assay 
is aimed at estimating the intracellular activity of the compounds, a crucial characteristic in drug discovery and 
development. A. castellanii cells were infected with GFP-expressing M. marinum. Intracellular bacterial growth 
was monitored by measuring the total fluorescence of GFP using a Synergy MX fluorescence plate reader37. 
Extracellular growth of M. marinum was inhibited by the presence of 10 μM amikacin in the medium. This 
compound is known to have low cellular permeability16 and, at this concentration, exerts selective bacteriostatic 
activity on bacteria outside host cells. Results of experiments performed as a biological triplicate are presented in 
Table S1 and classical kinetic curves of intracellular bacterial growth from the three plates are presented in Figs 3B 
and S4. The majority of the compounds decreased the rate of intracellular mycobacterial growth. However, 
only eight compounds (4.8%) possessed strong anti-infective activity, with more than 50% growth inhibition 
(Fig. S6B). Twenty-four showed moderate inhibition between 30 and 50% (Fig. 3C). Interestingly, twenty-three 
compounds (13.7%) also demonstrated clear pro-infective activity, resulting in more than 30% increase of bacte-
rial growth over the infection in the presence of the vehicle control.
Comparative anti-infective effects of compounds from the GSK TB-set on M. marinum growth 
in BV2 microglial cells. We established an infection assay based on the BV2 microglial cells and M. mari-
num expressing GFP to measure the anti-infective activity of compounds from the GSK TB set. The assay was 
designed to be as similar as possible to the A. castellanii assay for the ease of results comparison. For this, BV2 
cells were infected with GFP-expressing M. marinum and intracellular bacterial growth was monitored for three 
GSK ID
plate 
coordinate
Antibiotic assays
Growth inhibition/
Cytotoxicity assays Intracellular infection assays
Resistant 
mutants hit in BV2/ 
M. marinum 
assay
Hits A. 
castellanii/ 
M. marinum assay
M. marinum 
luxCDABE
M. marinum 
GFP
D. discoideum 
GFP-ABD
BV2 
cells
A. castellanii/ 
M. marinum BV2/M. marinum
M. bovis 
BCG
normalised growth, control = 1.00
True/
False normalised growth, control = 1.00
Potential 
target True/False True/False
10 µM, 
mean
10 µM, 
mean stdev
10 µM, 
mean stdev
10 µM 
mean
10 µM, 
mean stdev
10 µM, 
mean stdev IC50
GSK1055950A 2B04 0,00 −0,01 0,01 1,07 0,10 FALSE 0,24 0,12 0,33 0,24 2,84 ND TRUE TRUE
GSK1829732A 2F05 0,00 0,06 0,04 1,00 0,12 FALSE 0,56 0,08 0,34 0,17 3,52 ND TRUE FALSE
GSK1829676A 2C05 0,00 0,03 0,04 0,75 0,12 FALSE 0,56 0,25 0,35 0,20 −1,36 ND TRUE FALSE
GSK2111534A 2G07 0,00 0,06 0,05 0,83 0,14 FALSE 0,51 0,12 0,36 0,11 DHFR TRUE FALSE
GSK1829819A 2H05 0,00 0,08 0,06 1,08 0,10 FALSE 0,66 0,12 0,37 0,16 3,90 ND TRUE FALSE
GSK353496A 2B10 0,00 0,04 0,05 0,87 0,15 FALSE 0,57 0,09 0,39 0,15 7,84 DHFR TRUE FALSE
GSK3011724A 2C02 0,14 0,08 0,03 0,99 0,12 FALSE −0,32 0,22 0,40 0,05 4,44 Target identified TRUE TRUE
GSK1829736A 2C06 0,00 0,04 0,05 0,93 0,09 FALSE 0,60 0,19 0,41 0,30 2,21 ND TRUE FALSE
GSK353069A 1B06 0,00 0,01 0,02 0,99 0,10 FALSE 0,47 0,05 0,42 0,12 1,31 No Mutants TRUE TRUE
GSK1829728A 2G05 0,00 0,10 0,02 1,01 0,14 FALSE 0,78 0,39 0,43 0,08 4,03 ND TRUE FALSE
GSK1925843A 2H04 0,00 0,70 0,11 1,10 0,15 FALSE 1,12 0,39 0,43 0,29 3,83 ND TRUE FALSE
GSK1985270A 3G02 0,00 0,09 0,03 0,99 0,11 FALSE −0,06 0,06 0,45 0,16 4,88 ND TRUE TRUE
GSK498315A 1.00E+05 0,00 0,06 0,05 0,81 0,15 FALSE 0,56 0,02 0,47 0,10 5,95 ND TRUE FALSE
GSK1829729A 2D05 0,00 0,04 0,03 0,86 0,13 FALSE 0,52 0,08 0,48 0,40 0,08 ND TRUE FALSE
GSK695914A 1B07 0,00 0,05 0,08 0,98 0,08 FALSE 0,63 0,06 0,48 0,16 7,82 ND TRUE FALSE
GW861072X 2C09 0,00 0,05 0,06 0,68 0,08 FALSE 0,54 0,14 0,48 0,24 7,99 ND TRUE FALSE
GSK1829671A 2A05 0,00 0,06 0,10 1,21 0,22 FALSE 0,66 0,14 0,49 0,31 7,47 ND TRUE FALSE
GSK254610A 1H02 0,00 0,05 0,06 0,88 0,60 FALSE 0,87 0,13 0,50 0,03 ND TRUE FALSE
GR223839X 2F10 0,00 0,08 0,10 0,64 0,06 FALSE 0,70 0,31 0,50 0,30 7,35 ND TRUE FALSE
GSK1829820A 2A06 0,00 0,05 0,09 1,10 0,15 FALSE 0,49 0,14 0,65 0,63 −1,58 QcrB FALSE TRUE
GW369335X 3C02 0,20 0,14 0,06 0,97 0,02 FALSE 0,37 0,23 0,71 0,27 4,87 DHFR FALSE TRUE
GW664700A 2.00E+11 0,07 0,33 0,21 −0,01 0,03 FALSE −0,11 0,09 0,91 0,26 4,16 ND FALSE TRUE
GSK831784A 1H07 0,00 0,10 0,12 0,98 0,50 FALSE 0,20 0,24 0,97 0,34 14,96 MurC FALSE TRUE
Table 1. Selected hits from Table S1 detected by screening the GSK TB-set.
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days in the presence of 10 μM amikacin. For quantification of M. marinum growth, we used time-lapse imaging 
with a high-content fluorescence microscope (Fig. 4A–D,F). Results of two independent experiments are pre-
sented in Tables 1 and S1 and microscopy pictures are presented in Figure S7. Only 19 compounds (11.3%) were 
found to possess strong anti-infective activity, with more than 50% inhibition of bacteria growth (Figure S6A). 
Thirty showed moderate inhibition between 30 and 50%. Interestingly, 25 compounds (14.9%) also demonstrated 
clear pro-infective activity, resulting in more than 30% increase of bacterial growth during the infection in the 
presence of the vehicle control (Fig. 4G). Together, the results from both the A. castellanii- and BV2-based assays 
indicate a significant decrease in antibacterial activity of most compounds in comparison to the antibiotic assay 
in broth. These high attrition rates correspond in magnitude to the ones observed in most anti-tubercular screens, 
highlighting the biological significance and relevance of our screening systems13. Interestingly, we observe similar 
numbers of hits using the two infection systems, and the strongest hits are the same in the BV2 and A. castella-
nii based assays (see Tables 1 and S1, coloured in orange and dark red, respectively). In the case of the BV2/M. 
marinum infection assay, the IC50 of each compound was determined by high-content microscopy (Table S1, 
Figures S7, S8).
Amikacin does not significantly interfere with the detection of anti-infective hits against M. 
marinum during infection of BV2 cells. To determine whether amikacin affects the intracellular growth 
of M. marinum during infection, independently of, or in synergy with, the tested compounds. Amikacin is a 
crucial element in our infection assays, because it is continuously present in the medium at 10 μM. Amikacin has 
low cellular permeability15 and should not interfere with intracellular growth. The presence of amikacin in the 
medium during the course of the assay, and not only right after spinoculation, is important since we detect events 
of bacterial escape from the amoeba host36 that can lead to extracellular growth. However, our BV2 cell-based 
infection assay demonstrated insignificant numbers of bacterial escape (Video 1). This property of the BV2 host 
allowed us to compare the influence of amikacin on infection. We analysed the hit patterns emerging in the BV2 
Figure 2. Characterization of cytotoxic activities of GSK TB-set compounds. (a) Growth kinetics of D. 
discoideum GFP-ABD in HL5c medium and in the presence of 10 μM corresponded compounds from GSK 
TB set. (b) Pie chart representing summarized results of growth inhibitory activity of 168 compounds in BV2 
growth assay. The analysed set included compounds that displayed inhibition of more than 80% normalized 
RFU (red), moderate inhibition between 50 and 80% (orange), compounds that showed less than 50% inhibition 
(grey). (c) Bright-field microscopy of BV2 cells in the presence of non-cytotoxic compounds (upper image) of 
cytotoxic compounds (lower image. 105 BV2 cells were transferred to the wells, the measurements were taken 
after 60 hours of incubation. The scale bar corresponds to 500 µm.
www.nature.com/scientificreports/
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infection assay (described above) in the presence or absence of 10 μM amikacin, and found that amikacin does 
not influence hit identification. However, it should be noted that amikacin did affect the general fluorescence 
intensity of the bacterial load (Figure S7). Our results indicate that amikacin has an effect on mycobacteria growth 
inside BV2 cells, however, this effect did not significantly change the outcome of the screen.
Determination of antibacterial potency and structure-activity relationships of a set of 18 com-
pounds against M. marinum during infection of A. castellanii. The relative abundance of chemical 
analogs within the GSK TB-set allowed us to perform a limited set of structure-activity relationship studies in 
the case of the imidazo[1,2-a]pyridine-3-carboxamide family of compounds, represented with 18 compounds 
in the set analysed (Figures S9, S10). This family showed high anti-tubercular potency both in A. castellanii and 
BV2-based assays. Chemical similarity of compounds was estimated by Tanimoto coefficient and analysis of 
substructures. This family and its antitubercular activity was already mentioned in the literature41. Compounds 
were tested at 0.01, 0.1, 1, 2, 5, 10 and 20 µM in the A. castellanii/M. marinum system. MarivlSketch was used to 
visualize the compounds at atomic level. The GraphPad Prism software was used to generate MIC curves. Canvas 
with the Schrodinger package is used for calculation of nonlinear Kernel-based partial least squares regression 
(KPLS). The nonlinear regression was based on the data of 12 compounds with IC50 less than 20 µM. The KPLS 
regression model shows coefficient of similarly Q2 r0.0728 and regression coefficient R2 0.8043. The relatively low 
coefficient of predictability can be explained by the small size of the set of analysed compounds and low numbers 
of biological replicates. A significant increase in the number of chemical analogs will be required to construct 
more precise models of structure-activity interactions.
Identification of QcrB and KasA as molecular targets of GSK1829820A and GSK3011724A 
respectively and DHFR as a target of 30 small molecules of the GSK TB-set. A number of other 
compounds listed in the table have had their mode of action delineated in previous publications. The molecules 
that have been annotated as targeting DHFR (mycobacterial dihydrofolate reductase) were identified by in silico 
docking assay42. Spontaneous resistant mutants of M. bovis BCG were generated on solid mycobacterial media at 
5 times the MIC of the corresponding compound. Following the sequencing of the mutants and molecular genetic 
validation of the mode of action, the imidazo[1,2-a]pyridine compounds were found to target the b subunit of the 
Figure 3. Characterization of anti-infective activities of GSK TB-set compounds in protozoan infection assay. 
(a) Growth kinetics of M. marinum msp12::GFP in A. castellanii infection, 105 A. castellanii were transferred 
to the wells, 60 hours incubation time, PYG medium and in the presence of 10 μM corresponded compounds 
from GSK TB set. (b). Phase contrast/fluorescence microscopy of A. castellanii infection with M. marinum 
msp12::GFP. The scale bar corresponds to 30 μm. (c) Pie chart representing summarized results of growth 
inhibitory activity of 168 compounds in A. castellanii infection assay. The analyzed set included compounds that 
displayed inhibition of more than 50% normalized RFU (red), moderate inhibition between 30 and 50% (red), 
compounds that showed less than 30% inhibition (grey) and compounds that displayed increase of RFU by 
more than 30% (green). The scale bar corresponds to 200 µm.
www.nature.com/scientificreports/
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Figure 4. Characterization of anti-infective activities of GSK TB-set compounds in a mammalian infection 
assay. (a) Confocal microscopy of 105 BV2 microglial cells infected with M. marinum msp12::GFP, 60 hours 
incubation time in DMEM medium supplemented with bovine serum in a 96-well plate. Compounds derived 
from GSK TB-set were added at 10 μM dissolved in DMSO. (b) 3D-chart representing quantification of 
fluorescence in GSK TB-set. (c) Confocal/brightfield microscopy of BV2 cells infected with M. marinum 
msp12::GFP in the presence of vehicle control (B), cytotoxic (C), anti-infective (D) and pro-infective (E) 
compounds. 105 BV2 cells were transferred to the wells. (d) Pie chart representing summarized results of growth 
inhibitory activity of 168 compounds in A. castellanii infection assay. The analysed set included compounds that 
displayed inhibition of more than 50% normalized RFU (blue), moderate inhibition between 30 and 50% (red), 
compounds that showed less than 30% inhibition (grey) and compounds that displayed increase of RFU by 
more than 30% (yellow). The scale bar corresponds to 500 µm.
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mycobacterial cytochrome bc1 complex (QcrB). One of these compounds, GSK1829820A, has been identified in 
a high-content screen43. This method of mode of action elucidation by resistant mutant generation also previously 
provided the target of GSK3011724A, as inhibiting the essential long-chain fatty acid synthase enzyme β-ketoacyl 
synthase (kas) A44.
Identification of MurC as the target of GSK831784A and GSK847920A, and FbpA as the tar-
get of GW859039X. The mode of action of these new anti-mycobacterial compounds was discovered using 
a target-specific high-throughput screening technology, following a previously described method45 using M. 
bovis BCG over-expressing the essential mycobacterial genes murC (Rv2152c) and fbpA (Rv3804c), encoding 
the UDP-N-acetylmuramate-alanine ligase (MurC) and mycolyl transferase 85 fibronectin-binding protein A 
(Antigen 85 A), respectively. These overexpressing strains were used to probe the hit compounds identified in the 
A. castellanii -M. marinum infection high-throughput screen that had not previously had their mode of action 
delineated40. A commercially available luciferase reporter assay was used to measure cell viability of each strain 
following 7 days of incubation with each of the compounds at 1 and 10 μM in a 1536-well format. Hits were 
identified based on shift in apparent inhibition (calculated as % inhibition of M. bovis BCG pMV261 (empty 
plasmid) minus % inhibition of M. bovis BCG pMV261-murC/fbpA [based upon duplicate data]). Hit compounds 
were analysed using a serial dilution from 10 mM to 0.17 nM against M. bovis BCG pMV261 and M. bovis BCG 
pMV261- murC/fbpA. The percentage inhibition at each concentration was used to determine the XC50 (com-
pound concentration required to inhibit cell viability by 50%) of each compound against the over-expresser and 
empty vector strains based on duplicate data. This resulted in the identification of the mode of action of three 
of the compounds by XC50 shift upon target over-expression. The XC50 data for M. bovis BCG pMV261-murC 
against GSK831784A and GSK847920A, and M. bovis BCG pMV261-fbpA against GW859039 × along with the 
respective empty vector controls is shown in Fig. 5.
Identification of MmpL3 and GlpK as the targets of GSK2043267A and GSK1742694A, respec-
tively. Remaining hit compounds lacking mechanism of action delineation were entered into a pipeline of 
spontaneous resistant mutant generation, wherein resistant isolates were selected from 108 colony forming units 
of M. bovis BCG against compounds at high concentrations with respect to the minimal inhibitory concentration 
(MIC). Spontaneous resistant mutants were generated at 5 times the established MIC. Four resistant isolates were 
identified for GSK1742694A, and ten resistant isolates were identified for GSK2043267A. Phenotypic resistance 
was confirmed by plating resistant isolates at 0 and 5 times MIC alongside wild type M. bovis BCG (Figure S11). 
Upon confirmation of the resistance phenotype, the genomic DNA was isolated and sequenced (MicrobesNG) 
Figure 5. Identification of molecular targets of compounds from GSK TB-set. The shift in cell viability against 
a dose response of (a) GSK831784A and (b) GSK847920A upon over expression of MurC. Over expression of 
FbpA led to a shift in dose response to (c) GW859039X. (d) A tabulated summary of pXC50 shift values of each 
strain against the respective compounds.
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by Illumina sequencing. A resistance-conferring single nucleotide polymorphism (SNP) was identified in all ten 
of the resistant isolates raised against GSK2043267A, in the Mb0212c gene at position F255L (Ttc/Ctc) encoding 
MmpL3. Sequencing of the four mutants raised against GSK1742694A yielded a high-frequency SNP (ttG to 
ttC) corresponding to L385F in Mb3721c, encoding the glycerol kinase GlpK. Both of these genes have predicted 
essentiality in Mtb H37Rv46.
Discussion
In our study, we characterized 168 compounds from the GlaxoSmithKline TB-set in vivo, using protozoan and 
mammalian hosts for the infection with M. marinum as a model of Mtb. These chemicals were derived from an 
original GSK collection of 2 million compounds and display high antibiotic activities against M. bovis BCG and 
Mtb H37Rv, and low or no cytotoxicity in a HepG2 assay. We selected the murine microglial BV2 cells as a model 
of mammalian macrophage. The choice of protozoan hosts included the free-living amoebae A. castellanii and 
D. discoideum. Constitutive expression of GFP-reporters was used as the main readout for the quantification of 
prokaryotic and eukaryotic cell numbers. The methodology of the screening has already been established and 
validated with known antitubercular compounds in our lab37.
Here, we characterized the compounds in five different screens, including assays to monitor the intracellular 
growth of M. marinum in A. castellanii and BV2 microglial cells. We performed time-resolved measurements that 
are far superior and richer in information about the impact and mode of action of the compounds than the tra-
ditional end-point measurements. First, we detected the growth of M. marinum in Middlebrook 7H9 medium in 
the presence of compounds. The results of the screen are presented in Tables 1 and S1. The data revealed that 122 
compounds (72.0%) displayed significant inhibitory activity against M. marinum-GFP at a 10 μM concentration. 
The remaining 28.0% of the hits are probably not detected due to genetic and host-range differences between 
Mtb and M. marinum and possibly some technical factors. The use of an auto-bioluminescent M. marinum strain 
corroborated the data obtained with the GFP-fluorescent strain, but showed generally higher levels of inhibition 
of bacterial growth resulting in 94% of compounds displaying notable inhibition. The difference between the 
two assays most likely corresponds to the nature of the two readouts. While the bacterial luciferase-based assay 
depends on the bacteria ATP level and thus monitors both the total bacterial mass and metabolic status, the 
GFP-signal corresponds in first approximation to the bacterial mass of both live and dead mycobacteria. Indeed, 
it is known that the fluorescence does not go off immediately when bacteria are killed47. The choice between 
luminescence- and fluorescence-based readouts remains subjected to the balance between their intrinsic advan-
tages and limitations.
Overall, the antibiotic activity screen against M. marinum in broth displayed a substantial overlap with the 
results of the original screen against Mtb H37Rv40, despite the significantly shorter duration of the assay. This 
may speak in favour of M. marinum as a substitute for Mtb in antibiotic screening, given its ease of manipulation 
and cultivation, lower health and safety risks (biosafety level 2) and a fast growth rate that decreases the duration 
of experimental procedures. Additionally, because M. marinum is a fully active pathogen, unlike M. smegmatis 
or even M. bovis BCG, which are often used for compound screening, it offers the possibility to transition from 
single-cell assays to vertebrate organisms by using the powerful zebrafish infection system. In recent years, this 
system has become widely recognised as a strong alternative model to study the pathogenesis of TB40,48.
Estimation of the compounds’ cytotoxicity/growth inhibition activity was performed by monitoring the 
growth of GFP-ABD D. discoideum and BV2 cells. As a confirmation and expansion of the cytotoxicity tests 
performed in Ballel et al.40, only low numbers of cytotoxic activities were identified, 2.3% for D. discoideum 
and 3.2% for BV2, with 3 compound having cytotoxic activities in both assays. We observed a wider range of 
growth inhibitory activities in the D. discoideum assay. The observation of compounds in the TB-set showing 
cytotoxicity towards microglial cells seems surprising because they passed a standard HepG2 cytotoxicity assay40. 
Additionally, the A. castellanii-based growth inhibition assay provides results similar to the D. discoideum-based 
growth inhibition assay, confirming overall conservation of basic biological and metabolic pathways. In summary, 
compared to the original test performed on HepG2 cells40, D. discoideum is just as predictive of cytotoxic com-
pounds as any other mammalian cell line such as BV2. Given the overall advantages of D. discodeium, including 
the ease of genetic manipulation, this system generates new opportunities to quantitate cytotoxicity in any drug 
development process.
Our study reports a parallel and extensive comparison of the intracellular activity of anti-tubercular com-
pounds in both a protozoan model infection system (A. castellanii), and a mammalian macrophage cell line 
(microglial BV2 cells). We revealed a significant attrition of the antibacterial activity both in the A. castellanii and 
the BV2 infection systems. We detected 8 hits (4.8%) that inhibited more than 50% of the intracellular growth of 
M. marinum at 10 μM in A. castellanii and 19 hits (11.3%) in the BV2 microglial cells. We also identified 24 and 
30 moderate anti-infective hits with inhibition of 30 to 50% in the A. castellanii and BV2 cells, respectively. The 
inability of reaching 100% inhibition in most of the cases can be expected given the short duration of the assays 
(60–72 h) and stability of GFP-reporters used for mycobacteria quantification. Our data suggest that an incom-
plete yet reproducible inhibition might be sufficient for the detection of antibacterial hits. The higher stringency 
of the amoeba-based assay was expected because amoebae live in chemically challenging environments and are 
known to possess a large range of export pumps for xenobiotics49. However, the overall similar levels of attrition 
indicate that the evolutionary origin of the host cell, e.g. protozoan versus mammalian, is not the dominant 
factor in anti-infective hit identification. Instead, we suggest that the technical aspects of the screen may play an 
important role, including factors such as media composition, temperature, multiplicity of infection and others. 
The presence of amikacin in the medium might be one of these factors. In the BV2 infection assay, however, we 
did not find noticeable synergistic activity of amikacin with other compounds. Nevertheless, decreased bacteria 
growth indicated that amikacin exerts a significant effect on intracellular bacteria, despite previous reports15.
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A pronounced decrease in the number of compounds exerting a notable intracellular antibacterial activity 
is not so surprising and corresponds to the well-known high attrition rate in antibacterial drug discovery, for 
which, according to industry averages, the success rate is about 25% at early steps, while the complete process 
takes an astonishing 13 to 14 years13. In this regard, the A. castellanii infection assay revealed results compa-
rable to the microglial cell infection assay (see below) in terms of hit numbers. Indeed, four of the identified 
hits bear strong anti-infective properties in both assays including compounds GSK3011724A, GSK1985270A, 
GSK1055950A, GSK353069A. Among moderately anti-infective compounds, 21 were identified both in the 
amoeba and microglia-based assays. All the hits identified in infection assays showed strong antibiotic activities 
against M. marinum in bacterial broth. Our results show the A. castellanii-based assays to be predictive for activity 
in mammalian cells, although the amoeba assay is more stringent. This property may be beneficial for excluding 
inconclusive hits during hit-to-lead drug development.
On the other hand, identification of infection enhancers in the set of characterized antibiotic compounds was 
quite unexpected and has not been previously reported. Notably, we identified a certain number of pro-infective 
compounds, namely chemicals that increase the overall bacterial mass of M. marinum using both the BV2 and 
A. castellanii infection assays. 13% of the compounds demonstrated pro-infective activity in the A. castellanii 
infection assay and 14% in the BV2 cells infection assay. This type of activity may usually be largely ignored in 
TB drug screening campaigns. At the same time, such compounds may be beneficial for the understanding of 
drug action, because they may unveil important signalling pathways important for boosting anti-bacterial host 
defences. Intriguingly, the majority of identified pro-infective compounds were different in amoeba and mam-
malian cells-based assay (with an overlap of only 3 compounds), which indicates lower levels of conservation of 
pro-infective mechanisms compared to anti-infective activities. It must also be emphasized that the strongest 
pro-infective compounds (more than 70% increase) in the amoeba infection assay belong to the same chemical 
family (Table S1) and exclusively build-up this pro-infective class. We suggest a model that explains such activi-
ties (Fig. 6). We propose three main scenarios for the bacteria fates in the presence of the compound. In all three 
cases, it is important to note that the fluorescence intensity is proportional to bacterial mass, but bacteria remain 
fluorescent even when they die. The first scenario illustrates the standard bactericidal/bacteriostatic activities that 
result in a decrease of bacteria growth rates, as predicted. The second scenario takes into account the absence 
of significant bactericidal effect. In this case, the output is similar to an infection in the presence of the vehicle 
control, in which bacteria proliferate intracellularly and cause death of the host. The extracellular amikacin then 
restricts the bacterial mass. The third scenario represent the effect of compounds that induce a slight weakening of 
intracellular mycobacteria, lowering their cytotoxicity for the host cells. The access to the host resources and the 
shielding property of the host cell are therefore dominant factors, which lead to a relatively increased total mass 
of M. marinum compared to control conditions.
We identified four new molecular targets for compounds from the GSK TB-set. MmpL3 and GlpK are the 
targets of GSK2043267A and GSK1742694A, respectively. MurC is proposed as the target of GSK831784A and 
GSK847920A, and FbpA as the target of GW859039X. FbpA, a diacylglycerol acyltransferase/mycolyltransferase, 
synthesizes trehalose 6,6′-dimycolate, the key component of outer envelope in Mtb H37Rv. Mycolic acids of treha-
lose dimycolate also interact with the mycolyl-residues from the layer beneath. FbpA is a component of the anti-
gen 85 (Ag85) complex, which together with FbpB and FbpC. FbpA, has been shown to be crucial for the growth 
in nutrient-poor media and a macrophage-like cell line50. FbpA might play a crucial role in both cell wall stability 
and the biosynthesis of storage compounds for the survival of Mtb in the non-replicating persistent state during 
which mycobacteria use fatty acids as a carbon source. Another identified target, MurC is a member of Mur 
ligases, the key enzymes of the peptidoglycan biosynthesis pathway. Like fatty acids, peptidoglycans are essential 
components of the cell wall that provide a rigid support maintaining cell shape and turgidity. Mur synthetases are 
key enzymes in the cytoplasmic steps of PG biosynthesis. MurC initiates the synthesis of the stem peptide by addi-
tion of L-alanine (L-Ala) to the carboxyl group of uridine-diphospho-N-acetyl-muramic acid (UDP-MurNAc). 
It was shown that MurC was able to incorporate glycine (Gly) and L-Ala to UDP-MurNAc in both Mtb and M. 
leprae51. Munshi and colleagues (2013) observed that MurC synthetase from Mtb showed additional activity 
with L-Ser as confirmed by HPLC and LC-MS52. Fatty acid biosynthesis was also displayed by identification of 
MmpL3, essential mycolic acid transporter, as a target. Indeed, the inhibition of MmpL3 results in the abolition of 
the export of mycolic acids to the outer membrane and in the rapid killing of the bacilli53,54. There are 4 inhibitors 
already identified, displaying promising results based on efficacy, tolerability and pharmacological properties55–58. 
The high potency of these compounds displays vulnerability of the MmpL3 transporter both in vitro and in vivo53. 
GlpK is the key enzyme in the regulation of glycerol uptake and metabolism that catalyses the phosphorylation of 
glycerol to yield sn-glycerol 3-phosphate.
Only one of the compounds with identified molecular targets, GSK1742694A, displayed low antibiotic activity 
in our M. marinum growth assay. This is probably due to the short duration of the assay that prevents bacteria 
from exploiting their glycerol metabolism. However, GlpK could be a hit with no real physiological relevance, 
because our antibiotic screen as most whole-cell high throughput screens was performed with medium contain-
ing glycerol as the main carbon source, which raises a possibility of GlpK identification being a side effect of the 
selected experimental methodology. Example of such false positive hits are exemplified in a published study59. On 
the contrary, GSK2043267A, GSK831784A, GSK847920A, GW859039X displayed strong antibiotic activity in the 
M. marinum growth assay and variable activity in infection assays (Table S1).
Recently, Av-Gay and colleagues characterized 144 compounds of the GSK TB-set in Mtb-H37Rv-infected 
THP1 cells, using a luciferase reporter for bacterial quantification60 (Table S1). That assay displayed generally 
higher level of antibiotic activity, with 90.3% of the compounds confirmed as active in the intracellular envi-
ronment. The present study bears some similarities in scope and experimental strategy with that of Sorrentino 
et al.58, however it must be noted that the study of Av-Gay et al. uses Mtb instead of M. marinum, and of a mac-
rophage host cell line that is widely used in the field, compared to a microglial cell line. On the other hand, the 
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alternative amoeba host systems used in our study are intrinsically more stringent in terms of revealing intra-
cellular anti-infective molecules37–39, and because of the evolutionary distance automatically selects “universally 
active” compounds. In addition, while they used mainly an end-point measurement, we performed time-resolved 
measurements that are superior and richer in information about the impact and mode of action of the com-
pounds. Some other differences with our results may be caused by technical factors, specifically higher loads of 
intracellular bacteria in our assays (Video 1); the use of a luciferase versus a fluorescence reporter. Despite these 
differences, among the 10 most potent compounds identified60, 8 were also very potent in our luciferase-based 
assay. These compounds displayed variable activities in BV2 or A. castellanii infections, with GSK1985270A hav-
ing the most prominent antibacterial effect. Interestingly, we identified MmpL3 as a target of GSK1589673A, but 
have not identified resistant mutants in the case of GW623128X, GSK1589673A, GSK937733A GSK1589671A, 
compounds that are presumed to target MmpL360. Notably, 3 out of 10 compounds displayed pro-infective activ-
ity in our BV2 infection assay. Such an apparent reversal between anti- and pro-infective activity was observed 
for a few of the compounds when switching between the cellular models used for infection (see Table S1). This 
phenomenon might be explained by the three scenarios presented in Fig. 6.
Figure 6. Scenario for the pro-infective activity of some antibiotics. A compound with strong antibiotic activity 
simply kills bacteria inside the host and cures the infection, resulting in a rapid leveling of the total fluorescence 
intensity of GFP-expressing M. marinum. A compound that lacks anti-infective activity does not prevent 
intracellular mycobacterial growth, causing early proliferation of the bacteria and the death of the host. The 
bacteria kill their growth niche and thus loose access to host resources, which together with the extracellular 
activity of amikacin limits the maximal fluorescence increase. Counterintuitively, a compound with mild 
anti-infective activity will decrease the fitness and virulence of intracellular M. marinum, thereby limiting its 
cytotoxicity towards the host cell. The bacteria thus proliferate, use cellular resources and spread the infection 
without killing the host, reaching potentially higher maximal fluorescence.
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The present study represents a welcome diversification of the strategies for anti-TB drug discovery, which is 
important to increase the success rate of anti-TB screening campaigns. In particular, four new molecular targets 
have been identified. Therefore, because of the conservation of mechanism of action between M. marinum and 
Mtb as well as the fact that the compounds have anti-infective activities in multiple eukaryotic host systems, 
these molecules may have significant therapeutic potential. We expect that our effort with the use of classical and 
alternative whole cell-based TB screening for characterization of the GSK TB-set can support the fight against TB. 
Identification of drugs targeting cell wall stability and biosynthesis is an important step towards the elimination 
of the TB threat.
Materials and methods
Strains, transformation and culture. For M. marinum-based experiments the M strain was stably trans-
formed with the pMV306-luxCDABE expression plasmid61, rendering them auto-bioluminescent, or with the 
msp12::GFP expression vector (from Dr. L. Ramakrishnan)62 to obtain green-fluorescent bacteria. The myco-
bacteria strains described are available from the authors. For plasmid-carrying M. marinum strains, the growth 
medium was supplemented with 25 μg /ml kanamycin. Experiments for molecular target identification were per-
formed in M. bovis BCG that has been transformed by a standard heat shock protocol with pMV261, a kanamy-
cin-resistant mycobacterial over-expresser plasmid, which had been modified by addition of either Mtb murC 
(Rv2152c) or Mtb fbpA (Rv3804c). An empty vector strain (pMV261 only) was also prepared. Transformants were 
selected on Middlebrook 7H11 mycobacterial media (Difco) supplemented with 10% (v/v) OADC (oleic acid 
(1.25 × 10–2% v/v), albumin (1.25% w/v), dextrose (0.5% w/v) and catalase (1 × 10–3% w/v) (Sigma-Aldrich)), 
containing kanamycin at 25 μg.ml-1. Successful transformants were transferred into Middlebrook 7H9 liquid 
media (Difco) containing kanamycin at 25 μg.ml−1, 0.05% (v/v) Tween-80, 0.25% (v/v) glycerol and supple-
mented with 10% (v/v) ADC (albumin (1.25% w/v), dextrose (0.5% w/v) and catalase (7.5 × 10–4% w/v) (Sigma-
Aldrich)). Growth rate was monitored by measuring optical density (OD) at 600 nm and cells were passaged to 
maintain a mid-log OD600 of 0.4–0.8. To prevent mutagenesis, no more than 4 passages were conducted before 
cultures were reinitiated from a glycerol stock. In eukaryotic host-based assays A. castellanii (ATCC 30234)63 and 
murine microglial BV2 cells64 were utilized.
Antibiotic activity assay (M. marinum). GFP-expressing or luxCDABE-expressing M. marinum65 were 
cultivated in a shaking culture at 32 °C up to an OD600 of 0.8–1 in 7H9 medium supplemented with OADC. 105 
GFP-expressing M. marinum65 were transferred into each well of 96-well white plates. Bacterial growth at 32 °C 
was monitored by measuring the fluorescence, OD or luminescence in a plate reader (Synergy H1) for at least 
48 hours with a time point taken every 3 hours66 and by CFU counting. Rifabutin was added as a control at 10 µM 
concentration. Fluorescence excitation was at 485 nm and emission was monitored at 509 nm and light scattering 
measurements were performed at 600-nm. For CFU counting, samples were withdrawn and then serially diluted 
in saline solution (PBS). Aliquots of 100 μl were spread on 7H10 agar plates. After incubation at 32 °C, colonies 
were counted to determine the number of CFU.
Growth assay (D. discoideum). 104 GFP-ABD-expressing D. discoideum cells were transferred into each 
well of 96-well plates (Cell Carrier, black, transparent bottom from Perkin-Elmer), and allowed to attach for 
20–30 min. Cell growth at 25 °C was monitored by measuring the GFP fluorescence in a fluorescent plate reader 
(Synergy H1, company) for at least 48 hours with a time point taken every 3 hours.
A. castellanii infection assay. A. castellanii were cultured in PYG medium in 10 cm Petri dishes at 25 °C, 
and passaged the day prior to infection to reach 90% confluency. M. marinum were cultivated in a shaking culture 
at 32 °C to an OD600 of 0.8–1 in 7H9 medium. Mycobacteria were centrifuged onto a monolayer of A. castellanii 
cells at an MOI of 10 to promote efficient and synchronous uptake. Centrifugation was performed at RT at 500 g 
for two periods of 10 min. After an additional 20–30 min incubation, extracellular bacteria were washed off with 
PYG and infected cells were resuspended in PYG containing 10 μM amikacin. 5 × 104 infected cells were trans-
ferred to each well of a 96-well plate (Cell Carrier, black, transparent bottom from Perkin-Elmer) with preplated 
compounds and DMSO/rifabutin controls. The course of infection at 25 °C was monitored by measuring fluores-
cence in a plate reader (Synergy H1, BioTek) for 72 hours with time points taken every 3 hours. Time courses were 
plotted and data from all time points were used to determine the effect of compounds versus vehicle controls. To 
take into account possible autofluorescence of the compounds, RFU data of the first time point were subtracted 
from all time points. Cumulative curves were calculated. The activities of the compounds were determined by 
analysing maximum difference of compound cumulative curve to the 12–16 vehicle controls. For CFU counting, 
samples were withdrawn and then serially diluted in saline solution (PBS). Aliquots of 100 μl were spread on 
7H10 agar plates. After incubation at 32 °C, colonies on the plates were counted to determine the number of CFU.
BV2 cells infection assay. BV2 cells were cultured in DMEM medium supplemented with FCS in 10 cm 
Petri dishes at 37 °C. The day prior to infection, cells were trypsinized, passaged and transferred to 96-well plates 
(black transparent bottom from BD Falcon), so as to reach 60–70% confluency the day of the experiment. M. 
marinum were cultivated in a shaking culture at 32 °C up to an OD600 of 0.8–1 in 7H9 medium supplemented 
with OADC. Mycobacteria were centrifuged onto preplated BV2 cells at an MOI of 3 to promote efficient and syn-
chronous uptake. Centrifugation was performed at RT at 500 g for 10 min in a clinical centrifuge. After an addi-
tional 20 min incubation, extracellular bacteria were washed off with DMEM and infected cells were resuspended 
in DMEM supplemented with FCS. Compounds from the GSK TB set were added to a 30 µM final concentration. 
Infected cells were incubated at 32 °C. The course of infection was monitored by high-content microscopy with 
time points taken every 7–14 hours.
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High Content microscopy. Infected cells were monitored in 96-well plates (black, transparent bottom from 
BD Falcon). Recording of transmitted light and GFP fluorescence data were performed using ImageXpress Micro 
XL Widefield High-content Screening System (20 × 0.75 NA, air). Quantification of the image fluorescence inten-
sity was used to determine the effect of compounds versus vehicle controls. The activities of the compounds were 
determined by analysis of the maximum difference of fluorescence intensity at day 3 post-infection compared 
to 6–16 vehicle controls. High Content microscopy were used for conformation of IC50 data generated by single 
point measuring fluorescence in a plate reader (Synergy H1, BioTek).
Qualitative SAR studies. Compounds of interest were assayed at a range from 0.01 to 20 µM concentration 
in A. castellanii – M. marinum model, last data points values at 3 days post-infection were used to build dose 
response curve in Graph Pad Prism to determine IC50. A mean value from at least two biological replicates is 
given for each compounds.
High-throughput screening of hit compounds using murC and fbpA over-expressing strains of 
M. bovis BCG. Hit compounds with activity against M. marinum-infected D. discoideum identified in the 
high-throughput screen were tested for mechanism of action using murC and fbpA over-expressing strains of 
M. bovis BCG following the same methodology as previously described45. This was first conducted in single shot 
format at 10 and 1 μM, followed by a dose response validation of in serial dilution of 11 steps from 10 mM to 
0.17 nM using a 1/3 dilution factor all in a 50 nl total volume with relevant controls. All data regarding XC50 shift 
was obtained in duplicate.
M. bovis BCG spontaneous mutant generation and sequencing. The MIC of each compound against 
M. bovis BCG was determined on solid (Middlebrook 7H11) mycobacterial media and resistant mutants gen-
erated at 5 times the MIC. Resistant mutants were verified by plating back onto selective media alongside wild 
type before genomic DNA extraction and whole genome sequencing. The methodology herein is as described in 
Abrahams et al. 201243.
Data availability. Most data generated or analysed during this study are included in this published article 
(and its Supplementary Information files). Additional datasets generated and analysed during the current study 
are available from the corresponding authors on reasonable request.
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